Overview and recent advances in neuropathology: Part 2: Neurodegeneration

Pathology

Volumn 43, Issue 2, 2011, Pages 93-102

  Masters, Colin L ^a   Kril, Jillian J ^d   Halliday, Glenda M ^g   Collins, Steven ^b,c   Pamphlett, Roger ^h   Hill, Andrew F ^e   McLean, Catriona ^f  

^a FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^b Department of Pathology ^*  (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d MONASH UNIVERSITY   (Australia)

^e ALFRED HOSPITAL   (Australia)

^f UNIVERSITY OF SYDNEY   (Australia)

^g UNIVERSITY OF SYDNEY   (Australia)

^h UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

A synucleinAb amyloidpeptide; Alzheimer's disease; Amyloidproteinprecursor; Creutzfeldt Jakob disease; Dementia; Frontotemporal dementia; Frontotemporal lobar degeneration; Gene mutations; Humanprion diseases; Lewy bodies; Motor neuron disease; Parkinson's disease

Indexed keywords

BIOLOGICAL MARKER;

ALZHEIMER DISEASE; CLINICAL TRIAL; DEGENERATIVE DISEASE; FRONTOTEMPORAL DEMENTIA; GENETICS; HUMAN; LEWY BODY; METABOLISM; MOTOR NEURON DISEASE; MULTICENTER STUDY; PATHOLOGY; PRION DISEASE; REVIEW;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; FRONTOTEMPORAL LOBAR DEGENERATION; HUMANS; LEWY BODIES; MOTOR NEURON DISEASE; NEURODEGENERATIVE DISEASES; PRION DISEASES;

EID: 79955005316     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0b013e3283426eee     Document Type: Review

References (85)

1. Masters CL, Simms G,Weinman NA, et al. Amyloidplaque coreprotein in Alzheimer disease and Down syndrome.Proc Natl Acad Sci USA 1985; 82: 4245-9.
2. Kang J, Lemaire H-G, Unterbeck A, et al. Theprecursor of Alzheimer's disease amyloid A4protein resembles a cell-surface receptor. Nature 1987; 325: 733-6.
3. Duce JA, Tsatsanis A, Cater MA, et al. An iron-export ferroxidase activity of β-amyloidprotienprecursor is inhibited by zinc in Alzheimer's Disease. Cell 2010; 142: 857-67.
4. Lannfelt L, Blennow K, Zetterberg H, et al. Safety, efficacy and biomarker findings ofpBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: aphase IIa, double-blind, randomised,placebo-controlled trial. Lancet Neurol 2008; 7: 779-86. [Erratum. Lancet Neurol 2009; 8: 981.]
5. Rinne JO, Brooks DJ, Rossor MN, et al. 11C-PiBpET assessment of change in fibrillar amyloid-β load inpatients with Alzheimer's disease treated with bapineuzumab: aphase 2, double-blind,placebo controlled, ascending-dose study. Lancet Neurol 2010; 9: 363-72.
6. Ittner LM, Ke YD, Delerue F, Bi M, et al. Dendritic function of tau mediates amyloid-b toxicity in Alzheimer's disease mouse models. Cell 2010; 142: 387-97.
7. Zempel H, Thies E, Mandelkow E, et al. Aβ oligomers cause localized Ca2+ elevation, missorting of endogenous tau into dendrites, tauphosphorylation, and destruction of microtubules and spines. J Neurosci 2010; 30: 11938-50.
8. Ellis KA, Bush AI, Darby D, et al. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. Intpsychogeriatr 2009; 21: 672-87.
9. BourgeatP, Chételat G, Villemagne VL, et al. β-Amyloid burden in the temporal neocortex is related to hippocampal atrophy in subjects without dementia. Neurology 2010; 74: 121-7.
10. Villemagne VL,Perez KA,Pike KE, et al. Blood-borne amyloid-β dimmer correlates with clinical markers of Alzheimer's disease. J Neurosci 2010; 30: 6315-22.
11. Villemagne VL, Pike KE, Chételat, G, et al. Longitudinal assesment of Aβ and cognition in aging and Alzheimer's disease. Ann Neurol 2010; (inpress).
12. Lui JK, Laws SM, Li Q-X, et al.plasma amyloid-β as a biomarker in Alzheimer's disease: the AIBL study of aging. J Alzheimers Dis 2010; 20: 1233-42.
13. Chételat G, Villemagne VL, Bourgeat P, et al. Relationship between atrophy and β-amyloid deposition in Alzheimer disease. Ann Neurol 2010; 67: 317-24. [Editorial. Ann Neurol 2010; 67: 283-5.]
14. McKhann GM, Albert MS, Grossman M, Miller B, Dickson D, Trojanowski JQ. Clinical andPathological diagnosis of frontotemporal dementia. Arch Neurol 2001; 58: 1803-9.
15. Hodges JR, Mitchell J, Dawson K, et al. Semantic dementia: demography, familial factors and survival in a consecutive series of 100 cases. Brain 2010; 133: 300-6.
16. Kipps CM, Davies RR, Mitchell J, Kril JJ, Halliday GM, Hodges JR. Clinical significance of lobar atrophy in frontotemporal dementia: application of an MRI visual rating scale. Dement Geriatr Cogn Disord 2007; 23: 334-42. (Pubitemid 46631941)
17. Mackenzie IRA, Neumann M, Bigio EH, et al. Nomenclature and nosology for neuroPathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol 2010; 119: 1-4.
18. Mackenzie IRA, Neumann M, Bigio EH, et al. Nomenclature for neuroPathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathol 2009; 117: 15-8.
19. Broe GA, Hodges JR, Schofield E, Shepherd CE, Kril JJ, Halliday GM. Staging disease severity inPathologically confirmed cases of frontotemporal dementia. Neurology 2003; 60: 1005-11. (Pubitemid 36348937)
20. Schofield E, Kersaitis C, Shepherd CE, Kril JJ, Halliday GM. Severity of gliosis inpick's disease and frontotemporal lobar degeneration: tau-positive glia differentiate these disorders. Brain 2003; 126: 827-40. (Pubitemid 36372983)
21. Schofield EC, Caine D, Kril JJ, Cordato NJ, Halliday GM. Staging disease severity in movement disorder tauopathies: Brain atrophy separatesprogressive supranuclearpalsy from corticobasal degeneration. Mov Disord 2005; 20: 34-9. (Pubitemid 40277500)
22. Kril JJ, Halliday GM. ClinicoPathological staging of FTD severity: correlation with regional atrophy. Dement Geriatr Cogn Disord 2004; 17: 311-5. (Pubitemid 38721148)
23. Kril JJ, Macdonald V,Patel S,Png F, Halliday GM. Distribution of brain atrophy in behavioural variant frontotemporal dementia. J Neurol Sci 2005; 232: 83-90. (Pubitemid 40585847)
24. Kersaitis C, Halliday G, Kril JJ. Regional and cellularpathology in frontotemporal dementia: Relationship to stage of disease in cases with and withoutpick bodies. Acta Neuropathol (Berl) 2004; 108: 515-23. (Pubitemid 39534593)
25. Kersaitis C, Halliday G, Xuereb JH, et al. Ubiquitin-positive inclusions andprogression ofpathology in frontotemporal dementia and motor neuron disease identifies a group with mainly earlypathology. Neuropathol Appl Neurobiol 2006; 32: 83-91.
26. Hodges JR, Davies RR, Xuereb JH, et al. ClinicoPathological correlates in frontotemporal dementia. Ann Neurol 2004; 56: 399-406. (Pubitemid 39166559)
27. Josephs KA,petersen RC, Knopman DS, et al. ClinicoPathologic analysis of frontotemporal and corticobasal degenerations andpSP. Neurology 2006; 66: 41-8. (Pubitemid 43739589)
28. Ahmed Z, Mackenzie IRA, Hutton ML, Dickson DW.progranulin in frontotemporal lobar degeneration and neuroinflammation. J Neuroinflam 2007; 4: 7.
29. Gitcho MA, Bigio EH, Mishra M, et al. TARDBP 3′ -UTR variant in autopsy-confirmed frontotemporal lobar degeneration with TDP-43proteinopathy. Acta Neuropathol 2009; 118: 633-45.
30. Lewy FH. Zurpathologischen anatomie derparalysis Agitans. Dtsh Z Nervenheilk 1913; 50: 50-5.
31. Spillantini MG, Schmidt ML, Lee VM-Y, Trojanowski JQ, Jakes R, Goedert M. a-Synuclein in Lewy bodies. Nature 1997; 388: 839-40.
32. Eriksen JL,Przedborski S,petrucelli L. Gene dosage andpathogenesis ofparkinson's disease. Trends Mol Med 2005; 11: 91-6. (Pubitemid 40348985)
33. Dickson DW, Braak H, Duda JE, et al. NeuroPathological assessment ofparkinson's disease: refining the diagnostic criteria. Lancet Neurol 2009; 8: 1150-7.
34. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65: 1863-72. (Pubitemid 43970103)
35. Kovari E, Horvath J, Bouras C. Neuropathology of Lewy body disorders. Brain Res Bull 2009; 80: 203-10.
36. Braak H, Del Tredici K, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E. Staging of brainpathology related to sporadicparkinson's disease. Neurobiol Aging 2003; 24: 197-211. (Pubitemid 36007810)
37. Halliday G, Hely M, Reid W, Morris J. Theprogression ofpathology in longitudinally followedpatients withparkinson's disease. Acta Neuropathol 2008; 115: 409-15.
38. Brundinp, Li JY, Holton JL, Lindvall O, Revesz T. Research in motion: the enigma ofparkinson's diseasepathology spread. Nat Rev Neurosci 2008; 9: 741-5.
39. Merdes AR, Hansen LA, Jeste DV, et al. Influence of Alzheimerpathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology 2003; 60: 1586-90. (Pubitemid 36618082)
40. Weisman D, Cho M, Taylor C, Adame A, Thal LJ, Hansen LA. In dementia with Lewy bodies, Braak stage determinesphenotype, not Lewy body distribution. Neurology 2007; 69: 356-9.
41. Revuelta GJ, Rosso A, Lippa CF. Neuriticpathology as a correlate of synaptic loss in dementia with lewy bodies. Am J Alzheimers Dis Other Demen 2008; 23: 97-102.
42. Leverenz JB, Hamilton R, Tsuang DW, et al. Empiric refinement of thePathologic assessment of Lewy-relatedpathology in the dementiapatient. Brainpathol 2008; 18: 220-4. (Pubitemid 351430400)
43. NelsonpT, Abner EL, Schmitt FA, et al. Modeling the association between 43 different clinical andPathological variables and the severity of cognitive impairment in a large autopsy cohort of elderlypersons. Brainpathol 2010; 20: 66-79.
44. Clinton LK, Blurton-Jones M, Myczek K, Trojanowski JQ, LaFerla FM. Synergistic Interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci 2010; 30: 7281-9.
45. Zaccai J, Brayne C, McKeith I, Matthews F, IncepG.patterns and stages of alpha-synucleinopathy: Relevance in apopulation-based cohort. Neurology 2008; 70: 1042-8. (Pubitemid 351451312)
46. Morahan JM, Yu B, Trent RJ,Pamphlett R. A genome-wide analysis of brain DNA methylation identifies new candidate genes for sporadic amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2009; 10: 418-29.
47. Pamphlett R. Somatic mutation: a cause of sporadic neurodegenerative diseases? Med Hypotheses 2004; 62: 679-82. (Pubitemid 38530324)
48. Tan CF, Eguchi H, Tagawa A, et al. TDP-43 immunoreactivity in neuronal inclusions in familial amyotrophic lateral sclerosis with or without SOD1 gene mutation. Acta Neuropathol 2007; 113: 535-42. (Pubitemid 46672599)
49. Mackenzie IR, Bigio EH, IncepG, et al.Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol 2007; 61: 427-34. (Pubitemid 46878770)
50. Hasegawa M, Arai T, Nonaka T, et al.phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann Neurol 2008; 64: 60-70.
51. Pamphlett R, Kril J, Hng TM. Motor neuron disease: aprimary disorder of corticomotoneurons? Muscle Nerve 1995; 18: 314-8.
52. Pamphlett R, Luquin N, McLean C, Kum Jew S, Adams L. TDP-43 neuropathology is similar in sporadic amyotrophic lateral sclerosis with or without TDP-43 mutations. Neuropathol Appl Neurobiol 2009; 35: 222-5.
53. Pamphlett R, Kum Jew S. TDP-43 inclusions do notprotect motor neurons from sporadic ALS. Acta Neuropathol 008; 116: 221-2.
54. Pamphlett R. Study of 962patients indicatesprogressive muscular atrophy is a form of ALS. Neurology 2010; 74: 1926. [Author reply. Neurology 2010; 74: 1927.]
55. Incep, Stout N, Shawp, et al.parvalbumin and calbindin D-28k in the human motor system and in motor neuron disease. Neuropathol Appl Neurobiol 1993; 19: 291-9.
56. Baloh RH, Rakowicz W, Gardner R,Pestronk A. Frequent atrophic groups with mixed-type myofibers is distinctive to motor neuron syndromes. Muscle Nerve 2007; 36: 107-10. (Pubitemid 47016169)
57. Collins SJ, Lawson VA, Masters CL. Transmissible spongiform encephalopathies. Lancet 2004; 363: 51-61. (Pubitemid 38076927)
58. Prusiner SB. Novelproteinaceous infectiousparticles cause scrapie. Science 1982; 216: 136-44.
59. Legname G, Baskakov IV, Nguyen HO, et al. Synthetic mammalianprions. Science 2004; 305: 673-6.
60. Castilla J, Saáp, Hetz C, et al. In vitro generation of infectious scrapieprions. Cell 2005; 121: 195-206.
61. Wang F, Wang XH, Yuan CG, et al. Generating aprion with bacterially expressed recombinantprionprotein. Science 2010; 327: 1132-5.
62. Collins S, Boyd A, Lee JS, et al. Creutzfeldt-Jakob disease in Australia 1970-1999. Neurology 2002; 59: 1365-71. (Pubitemid 35285988)
63. Ladogana A,Puopolo M, Croes EA, et al. Mortality from Creutzfeldt-Jakob disease and related disorders in Europe, Australia, and Canada. Neurology 2005; 64: 1586-91. (Pubitemid 40617696)
64. Windl O, Dempster M, Estibeiro J, et al. Genetic basis of Creutzfeldt-Jakob disease in the United Kingdom - a systematic analysis ofpredisposing mutations and allelic variation in thepRNP gene. Hum Genet 1996; 98: 259-64. (Pubitemid 26258371)
65. Kovács GG,Puopolo M, Ladogana A, et al. Geneticprion disease: the EUROCJD experience. Hum Genet 2005; 118: 166-74.
66. Collins SJ, Schuur M, Boyd A, et al. No evidence forprionprotein gene locus multiplication in Creutzfeldt-Jakob disease. Neurosci Lett 2010; 472: 16-8.
67. Parchip, Giese A, Capellari S, et al. Classification of sporadic Creutzfeldt- Jakob disease based on molecular andphenotypic analysis of 300 subjects. Ann Neurol 1999; 46: 224-33. (Pubitemid 29382879)
68. Bishop MT, Will RG, Manson JC. Defining sporadic Creutzfeldt-Jakob disease strains and their transmissionproperties.Proc Natl Acad Sci USA 2010; 107: 12005-10.
69. Cali I, Castellani R, Alshekhlee A, et al. Co-existence of scrapieprionprotein types 1 and 2 in sporadic Creutzfeldt-Jakob disease: its effect on thephenotype andprion-type characteristics. Brain 2009; 132: 2643-58.
70. Collins SJ, Sanchez-JuanP, Masters CL, et al. Determinants of diagnostic investigation sensitivities across the clinical spectrum of sporadic Creutzfeldt- Jakob disease. Brain 2006; 129: 2278-87. (Pubitemid 44522114)
71. Gambettip, Dong Z, Yuan J, et al. A novel human disease with abnormalprionprotein sensitive toprotease. Ann Neurol 2008; 63: 697-708. (Pubitemid 351945529)
72. Collins S, McLean CA, Masters CL. Gerstmann-Sträussler-Scheinker syndrome, fatal familial insomnia, and kuru: a review of these less common human transmissible spongiform encephalopathies. J Clin Neurosci 2001; 8: 387-97. (Pubitemid 32843688)
73. Medori R, Tritschler H, LeBlanc A, et al. Fatal familial insomnia, aprion disease with a mutation at codon 178 of theprionprotein gene. N Engl J Med 1992; 326: 444-9.
74. Brownp,Preece M, Brandel JP, et al. Iatrogenic Creutzfeldt-Jakob disease at the millennium. Neurology 2000; 55: 1075-81.
75. Collinge J, Whitfield J, McKintosh E, et al. Kuru in the 21st century-an acquired humanprion disease with very long incubationperiods. Lancet 2006; 367: 2068-74. (Pubitemid 43949290)
76. Will RG, Ironside JW, Zeidler M, et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 1996; 347: 921-5. (Pubitemid 26102546)
77. Hill AF, Butterworth RJ, Joiner S, et al. Investigation of variant Creutzfeldt- Jakob disease and other humanprion diseases with tonsil biopsy samples. Lancet 1999; 353: 183-9. (Pubitemid 29088029)
78. Llewelyn CA, HewittpE, Knight RS, et al.possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 2004; 363: 417-21. (Pubitemid 38210057)
79. Ironside JW, Bishop MT, Connolly K, et al. Variant Creutzfeldt-Jakob disease:prionprotein genotype analysis ofpositive appendix tissue samples from a retrospectiveprevalence study. BMJ 2006; 332: 1186-8. (Pubitemid 44365449)
80. Hsich G, Kinney K, Gibbs CJ, et al. The 14-3-3 brainprotein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies. N Engl J Med 1996; 335: 924-30. (Pubitemid 26314445)
81. Zerr I, Kallenberg K, Summers DM, et al. Updated clinical diagnostic criteria for sporadic Creutzfeldt Jakob disease. Brain 2009; 132: 2659-68.
82. Atarashi R,Wilham JM, Christensen L, et al. Simplified ultrasensitiveprion detection by recombinantprP conversion with shaking. Nat Methods 2008; 5: 211-2. (Pubitemid 351325633)
83. Ritchie DL, Head MW, Ironside JW. Advances in the detection ofprionprotien inperipheral tissues of variant Creutzfeldt-Jakob diseasepatients usingparaffin-embedded tissue blotting. Neruopathol Appl Neurobiol 2004; 30: 360-8. (Pubitemid 39120297)
84. Boyd A, Klug GM, Schonberger LB, et al. Iatrogenic Creutzfeldt-Jakob disease in Australia: time to amend infection control measures forpituitary hormone recipients? MJA 2010; 193: 366-9.
85. Mackenzie IRA, Baborie A,Pickering-Brown SM, et al. Heterogeneity of ubiquitinpathology in frontotemporal lobar degeneration: classification and relation to clinicalphenotype. Acta Neuropathol 2006; 112: 539-49.